Please login to the form below

Not currently logged in

Pfizer pays $680m to buy ADHD drug developer NextWave

Portfolio includes once-daily Quillivant XR

Pfizer has agreed to buy NextWave Pharmaceuticals for $680m in a deal that would bring it a franchise in drugs to treat attention deficit hyperactivity disorder (ADHD).

The pharma giant took a $20m option to merge with NextWave earlier this year and has now followed that up with a full acquisition offer of $255m, plus sales milestones of up to $425m. Pfizer said the transaction is expected to close later this year.

The primary asset held by NextWave is Quillivant XR (methylphenidate HCl), an extended-release ADHD drug in a child-friendly liquid formulation that can be given just once a day before school. 

The product fills a void in ADHD treatment as it provides an alternative to tablets or capsules for patients who have difficulty taking them, but also provides cover for the entire day with a single dose, thereby avoiding any stigma that may be associated with taking medicines in school.

The product was developed in partnership with drug delivery specialist Tris Pharma and has just been granted marketing approval in the US, with NextWave holding exclusive marketing rights in North America.

Quillivant XR's clinical profile should help it make inroads into a global ADHD market estimated to be worth around $4bn and growing at 8 per cent a year, according to GlobalData estimates.

The market in the US has been dominated for some time by Shire - with products such as Daytrana (methylphenidate; now divested to Noven Pharma), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine) - and Johnson & Johnson with its Concerta (methylphenidate) product.

Generic versions of older ADHD drugs such as Shire's Adderall XR (mixed amphetamine salts) are starting to change the dynamics of the market, however. Meanwhile, with even second-generation therapies such as Concerta now facing patent expiry, newer products will need clear advantages - as well as marketing muscle - to differentiate themselves in the marketplace.

In addition to Quillivant XR, NextWave is developing a chewable tablet formulation of methylphenidate - codenamed NWP09 - that is due to be filed for approval in 2013.

23rd October 2012

From: Sales



Related Hub content

Featured jobs

Subscribe to our email news alerts


Add my company

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

‘Less Is More: Making Patient-Centered Digital Communication a Reality’
Letizia Affinito writes on the Gower Publishing blog....
The Seven Cs Of Cross-Functional Brand Planning
As more and more organisations have moved to cross-functional and cross-regional involvement in the development of their strategic and operational brand plans, the result has been greater engagement and alignment,...
2015/16 Pharmaceutical Titles
Browse our latest interactive Pharmaceutical and Healthcare catalogue...